47 results about "Renal inflammation" patented technology

A remedy and/or a preventive for a chronic disease which contains an EDG-2 antagonist. Because of binding to a subtype EDG-2 of LPA receptor, an EDG-2 antagonist is useful in treating and/or preventing chronic diseases (for example, diseases caused by the progress of chronic asthma, glomerular nephritis, obesity, arteriosclerosis, rheumatoid and atopic diseases) induced and made chronic by tissue cells whose proliferation is accelerated by LPA mediated by EDG-2.

The invention relates to a new kidney target medicine carrier and relative precursor medicine, relative preparation method and application, wherein it comprises: degrading and deriving the natural chitose to obtain the chitose or its derivant with low molecule weight, with better kidney target proerpty; said medicine carier via chemical bond is linked to the anti-cancer medicine or glucocorticoids, or immunosuppressant, to obtain the precursor medicine; the medicine molecule is connected to the carrier via chemical bond. The experiments have proved that: said medicine can release the active component at kidney. And the invention has simple process, stable property and the application for batch production.

The present invention relates to a medicament comprising the compound of formula (I)

wherein all symbols have the same meanings as defined in the specification, a salt thereof or a prodrug thereof. The compound of the present invention is useful for the prevention and/or treatment of immune diseases such as various types of inflammation, autoimmune disease, allergic diseases, etc.; infection concerning inflammation or HIV infections (e.g. asthma, nephritis, nephropathy, hepatitis, arthritis, rheumatoid arthritis, rhinitis, conjunctivitis, ulcerative colitis, etc.), organ transplantation rejection, immunosuppression, psoriasis, multiple sclerosis, optic neuritis, polymyalgia rheumatica syndrome, uveitis, vasculitis, human immunodeficiency virus infection (acquired immunodeficiency syndrome etc.), atopic dermatitis, urticaria, allergic bronchopulmonary aspergillosis, allergic eosinophilic gastroenteritis, osteoarthritis, ischemic reperfusion injury, acute respiratory distress syndrome, shock accompanying bacteria infection, diabetes, cancer metastasis, atherosclerosis, etc.).

A pharmaceutical composition is provided for treatment and/or prevention of a disease, a disorder and/or a condition caused by expression of a gene controlled by NF-κB or ets. The composition comprises at least one decoy and a pharmaceutically acceptable carrier. The decoy is an NF-κB decoy, an ets decoy, or a chimera decoy of NF-κB and ets. The disease is cerebral aneurysm, cancer, Marfan's syndrome, aortic detachment, post-angioplasty restenosis, chronic articular rheumatism, asthma, atopic dermatitis, nephritis, renal failure, or plaque rupture. Alternatively, the disease is a disease associated with eosinophilic abnormality (e.g., asthma, vascular diseases, allergic diseases, parasite diseases). The pharmaceutically acceptable carrier may be a hydrophilic polymer, a liposome, or the like.

The invention discloses a kidney essence pill formula for treating chronic pyelonephritis and a preparation method of the kidney essence pill, belonging to the technical field of traditional Chinese medicine formula. The kidney essence pill comprises the following raw materials of effective ingredients in parts by weight: 20-38g of rhizoma smilacis glabrae, 15-30g of Chinese yam, 15-30g of phymatopsis hastata, 10-30g of red bean, 10-30g of semen coicis, 12-28g of oyster, 9-24g of tortoise shell, 6-15g of morinda officinalis, 9-15g of lophatherum gracile, 7-15g of cortex lycii radicis, 5-12g of rhizoma alismatis, 4-12g of sparganii rhizoma, 4-10g of earthworm, 3-11g of myrrh, 3-9g of salvia miltiorrhiza, 3-9g of golden cypress, 3-8g of tangerine seed, and 1-3g of endothelium corneum gigeriae galli. The kidney essence pill formula is perfect in selecting raw materials and unique in compatibility of medicines, aims at pathogeny of nephritis such as spleen-kidney-yang deficiency, urination disorder, and retention of damp-heat in the interior, has effects on clearing heat and promoting diuresis, detoxifying and treating stranguria, inducing diuresis to alleviate edema, tonifying kidney and nourishing blood. The kidney essence pill is prepared through reasonable combination of raw materials. Clinical verification shows that the kidney essence pill has good absorption effect, obvious curative effect, no toxic and side effects, and no clinical adverse reaction, meets clinical requirements, is an ideal pill for curing kidney.

Disclosed is a composition of matter of the formula (X<1>)a-(F<1>)d-(X<2>)b-(F<2>)e-(X<3>)c and multimers thereof, in which F<1> and F<2> are half-life extending moieties, and d and e are each independently 0 or 1, provided that at least one of d and e is 1; X<1>, X<2>, and X<3> are each independently -(L)f-P-(L)g-, and f and g are each independently 0 or 1; P is a toxin peptide of no more than about 80 amino acid residues in length, comprising at least two intrapeptide disulfide bonds; L is an optional linker; and a, b, and c are each independently 0 or 1, provided that at least one of a, b and c is 1. Linkage to the half-life extending moiety or moieties increases the in vivo half-life of the toxin peptide, which otherwise would be quickly degraded. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are a DNA encoding the inventive composition of matter, an expression vector comprising the DNA, and a host cell comprising the expression vector. Methods of treating an autoimmune disorder, such as, but not limited to, multiple sclerosis, type 1 diabetes, psoriasis, inflammatory bowel disease, contact-mediated dermatitis, rheumatoid arthritis, psoriatic arthritis, asthma, allergy, restinosis, systemic sclerosis, fibrosis, scleroderma, glomerulonephritis, Sjogren syndrome, inflammatory bone resorption, transplant rejection, graft-versus-host disease, and lupus and of preventing or mitigating a relapse of a symptom of multiple sclerosis are also disclosed.

The present application relates to novel 2,5-disubstituted 6-(trifluoromethyl)pyrimidin-4(3H)-one derivatives, to processes for their preparation, to their use alone or in combinations for the treatment and/or prevention of diseases, and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for treatment and/or prevention of cardiovascular, renal, inflammatory and fibrotic diseases.

The present invention relates to a compound of formula (I) wherein R⁴ is C1-6alkyl, halogen or cyano; R⁵ is halogen; R² is 4,5,6,7-tetrahydropyrazolo[3,4-c]pyridinyl which is unsubstituted or substituted by C1-6alkyl or haloC1-6alkyl; 4,5,6,7-tetrahydropyrazolo[4,3-c]pyridinyl which is unsubstituted or substituted one or two times by C1-6alkyl; or 5,6-dihydro-4H-pyrrolo[3,4-c]pyrazolyl; R³ is C1-6alkyl; L is azetidinyl or piperidinyl; or a pharmaceutically acceptable salt thereof, for use as a TLR7, TLR8 and/or TLR9 antagonist for the treatment or prophylaxis of autoimmune diseases, such as e.g. systemic lupus erythematosus or lupus nephritis.

The invention provides a GAOH derivative of a new structure. The compounds have great curative effects on inflammatory bowel diseases, hepatitis viruses, foot swelling, ear swelling, arthritis, pneumonia, nephritis, rhinitis, cerebral apoplexy, myocardial ischemia, atherosclerosis, arrhythmia, autoimmune disease, senile dementia, depression, schizophrenia, malignancy and tumor adjuvant therapy, virus infectious diseases, peptic ulcer, analgesia, antianaphylaxis, antiendotoxin, antishock and diabetes or diabetic complication.

The present invention relates to a pharmaceutical composition containing a SIRT2 inhibitor and, more specifically, to: a pharmaceutical composition for preventing or treating renal inflammatory diseases, which are caused by sepsis, by controlling inflammation-inducing factors by sepsis through the regulation of SIRT2 gene expression so as to reduce renal inflammation, thereby preventing a kidney injury; and a pharmaceutical composition for preventing or treating cancer, having an effect of increasing anticancer efficacy while reducing nephrotoxicity, which is a side effect of cisplatin, when administered together with cisplatin.

The invention discloses application of an ferroptosis inhibitor as an active ingredient in preparation of a drug for treating systemic lupus erythematosus. Researches find that neutrophils of an SLE patient spontaneously generate ferroptosis, and the neutrophils return to normal after effective systemic treatment. The ferroptosis inhibitor liproxstatin-1 (LPX-1) can be used for delaying the deathrate of neutrophils and inhibiting ferroptosis. The Crispr/cas9 technology demonstrates that increased ferroptosis can enable C57/B6 mice to spontaneously develop lupus phenotype. In an MRL/lpr mice model, the LPX-1 treatment can slow down the progress of lupus diseases, and the spleen, lymph node size, nephritis and proteinuria levels, deposition of renal immune complexes, and levels of inflammatory factors in the treated mice are similar to those in the cyclophosphamide-treated group, indicating that the treatment effect of LPX-1 is similar to that of cyclophosphamide. Due to different action mechanisms, the LPX-1 does not have cytotoxicity similar to cyclophosphamide, so that the LPX-1 can be a better lupus treatment drug.

The present invention relates to an assay for detecting Tumstatin, and its use in evaluating lung cancers, such as non-small cell lung cancer (NSCLC), chronic kidney disease (CKD), such as CKD resulting from diabetes, lupus nephritis (LN) and systemic lupus erythematosus (SLE).

The invention discloses application of salvianolic acid A in pharmacy, and relates to application of salvianolic acid A in terms of preparation of medicines for suppressing activation of renal fibroblasts and intercapillary cells, preparation of medicines for reducing renal fibrosis, preparation of medicines for improving urine protein, preparation of medicines for improving renal functions, preparation of medicines for relieving renal inflammation and collagen deposition and preparation of medicines for relieving related genes and protein of renal fibrosis indexes. A screening platform for activation of renal fibroblasts and intercapillary cells of mice induced by TGF (transforming growth factor)-beta 1 is designed, and experiments show that from 4.94X10-5g/ml to 4.94X10-5g/ml of salvianolic acid A can suppress activation of the renal fibroblasts and intercapillary cells of the mice induced by the TGF-beta 1. A vitro experiment of the salvianolic acid A functioning to the mice in a UUO (unilateral ureteral obstruction) model and a Platt model is further designed and shows that medium-dosage salvianolic acid A (10mg/kg/d) and high-dosage salvianolic acid A (17.1mg/kg/d) can reduce urine protein, renal functions and related genes and protein of renal fibrosis of the mice in the UUO model and the Platt model.

The invention belongs to the technical field of bio-pharmaceuticals, and provides application of a benzimidazole compound serving as an immunosuppressor in preparation of medicines for treating autoimmune diseases in the presence of T cells, such as inflammatory bowel disease, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus and autoimmunenephritis. A series of novel compounds synthesized by the benzimidazole compound have the advantages of being remarkable in efficacy, novel in mechanism, effective in oral taking, and less in toxic and side effects; and compared with a conventional medicine, the benzimidazole compound is remarkably advantaged in simple synthesis route and environment-friendly.

This invention relates to a combination drug comprising a combination of a tetrazolylalkoxy-dihydrocarbostyril derivative of the formula:

wherein R is cycloalkyl, A is lower alkylene, and the bond between 3- and 4-positions of carbostyril nucleus is single bond or double bond, or a salt thereof and Probucol, which is useful for preventing and treating cerebral infarction including acute cerebral infarction and chronic cerebral infarction, arteriosclerosis, renal diseases (e.g. diabetic nephropathy, renal failure, nephritis), and diabetes owing to synergistic superoxide suppressant effects of the combination.